Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Retained Earnings (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Retained Earnings data on record, last reported at $50000.0 in Q4 2025.

  • For Q4 2025, Retained Earnings fell 5.66% year-over-year to $50000.0; the TTM value through Dec 2025 reached $50000.0, down 5.66%, while the annual FY2025 figure was $50000.0, 5.66% down from the prior year.
  • Retained Earnings reached $50000.0 in Q4 2025 per CCCC's latest filing, up from -$718.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $455000.0 in Q3 2024 and bottomed at -$718.2 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$199.3 million, with a median of -$3.1 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 231319.35% in 2022, then surged 100.09% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$267.7 million in 2021, then crashed by 47.88% to -$395.9 million in 2022, then crashed by 33.47% to -$528.4 million in 2023, then soared by 100.01% to $53000.0 in 2024, then fell by 5.66% to $50000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $50000.0 in Q4 2025, -$718.2 million in Q3 2025, and -$30000.0 in Q2 2025.